SCENT part 2. Identification of patients with lung cancer and breast cancer.

Smellprints in lung Cancer; the role of ENose in diagnosis and Treatment (SCENT): part 2. Identification of patients with lung cancer and breast cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON27863

Enrollment

300

Registered

2008-12-29

Start date

2009-01-02

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

smell-print electronic Nose exhaled breath lung cancer breast cancer

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: All patients (18-80 yr) referred to the outpatient department pulmonary diseases for suspicion of lung cancer and at the outpatient department of surgery for suspicion of breast cancer.

Exclusion criteria

Exclusion criteria: None, exept impossibillity to make a diagnosis or folow the instructions prior to the measurement.

Design outcomes

Primary

Measure	Time frame
Sensitivity, specificity, positive and negative predictive value of the eNose in detecting NSCLC or breast cancer.	—

Secondary

Measure	Time frame
Sensitivity, specificity, positive and negative predictive value of the eNose in detecting subtypes of NSCLC (adenocarcinoma or squamous cell carcinoma)	—

Contacts

Public ContactJ. Maten, van der

Dept. of pulmonary diseases MCL Leeuwarden

j.maten@znb.nl+31 (0)58 286 6190

Outcome results